NO328927B1 - Anvendelse av fluorinerte triazoler til behandling av smerte og smertefulle lidelser - Google Patents
Anvendelse av fluorinerte triazoler til behandling av smerte og smertefulle lidelser Download PDFInfo
- Publication number
- NO328927B1 NO328927B1 NO20014180A NO20014180A NO328927B1 NO 328927 B1 NO328927 B1 NO 328927B1 NO 20014180 A NO20014180 A NO 20014180A NO 20014180 A NO20014180 A NO 20014180A NO 328927 B1 NO328927 B1 NO 328927B1
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- pain
- formula
- drug
- use according
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 7
- 208000035475 disorder Diseases 0.000 title abstract description 7
- 150000003852 triazoles Chemical class 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 14
- 208000004296 neuralgia Diseases 0.000 claims description 13
- 208000021722 neuropathic pain Diseases 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
- POGQSBRIGCQNEG-UHFFFAOYSA-N rufinamide Chemical compound N1=NC(C(=O)N)=CN1CC1=C(F)C=CC=C1F POGQSBRIGCQNEG-UHFFFAOYSA-N 0.000 claims description 5
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 208000001387 Causalgia Diseases 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 210000003461 brachial plexus Anatomy 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 abstract description 3
- 238000012423 maintenance Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 208000004454 Hyperalgesia Diseases 0.000 description 7
- 230000003542 behavioural effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000002981 neuropathic effect Effects 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- -1 2,5-difluorophenyl Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010041243 Social avoidant behaviour Diseases 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229940127558 rescue medication Drugs 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010013142 Disinhibition Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 108091002531 OF-1 protein Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- 229960000305 enflurane Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 208000037870 generalized anxiety Diseases 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/259,911 US6054471A (en) | 1999-03-01 | 1999-03-01 | Use of fluorinated triazoles in treating neuropathic pain |
| US09/259,910 US6156775A (en) | 1999-03-01 | 1999-03-01 | Use of fluorinated triazoles in treating affective and attention disorders |
| PCT/EP2000/001626 WO2000051577A2 (en) | 1999-03-01 | 2000-02-28 | Use of fluorinated triazoles for treating pain and affective or attention disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20014180D0 NO20014180D0 (no) | 2001-08-28 |
| NO20014180L NO20014180L (no) | 2001-08-28 |
| NO328927B1 true NO328927B1 (no) | 2010-06-14 |
Family
ID=26947613
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20014180A NO328927B1 (no) | 1999-03-01 | 2001-08-28 | Anvendelse av fluorinerte triazoler til behandling av smerte og smertefulle lidelser |
| NO20092921A NO334104B1 (no) | 1999-03-01 | 2009-08-31 | Anvendelse av fluorinerte triazoler til behandling av affektive forstyrrelser og oppmerksomhetsforstyrrelser. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20092921A NO334104B1 (no) | 1999-03-01 | 2009-08-31 | Anvendelse av fluorinerte triazoler til behandling av affektive forstyrrelser og oppmerksomhetsforstyrrelser. |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP1609505B1 (ko) |
| JP (1) | JP4700195B2 (ko) |
| KR (2) | KR100839765B1 (ko) |
| CN (2) | CN1636562A (ko) |
| AT (1) | ATE303179T1 (ko) |
| AU (1) | AU764508B2 (ko) |
| BR (1) | BR0008606A (ko) |
| CA (1) | CA2362411C (ko) |
| CY (1) | CY1115241T1 (ko) |
| DE (1) | DE60022317T2 (ko) |
| DK (2) | DK1156856T3 (ko) |
| ES (2) | ES2441208T3 (ko) |
| HK (1) | HK1086775A1 (ko) |
| HU (2) | HU227602B1 (ko) |
| ID (1) | ID29891A (ko) |
| IL (3) | IL144852A0 (ko) |
| NO (2) | NO328927B1 (ko) |
| NZ (1) | NZ513716A (ko) |
| PL (2) | PL199660B1 (ko) |
| PT (1) | PT1609505E (ko) |
| RU (1) | RU2238725C2 (ko) |
| SI (1) | SI1609505T1 (ko) |
| SK (2) | SK286775B6 (ko) |
| TW (1) | TW513301B (ko) |
| WO (1) | WO2000051577A2 (ko) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2905878T3 (es) | 2015-01-30 | 2022-04-12 | Neurocrine Biosciences Inc | Triazoles sustituidos y métodos relacionados con los mismos |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1511195A (en) * | 1976-10-18 | 1978-05-17 | Ici America Inc | Triazole derivatives |
| FI93544C (fi) * | 1985-04-18 | 1995-04-25 | Ciba Geigy Ag | Menetelmä fluorattujen, antikonvulsiivisesti vaikuttavien 1-bentsyyli-1H-1,2,3-triatsoliyhdisteiden valmistamiseksi |
-
2000
- 2000-02-22 TW TW089103041A patent/TW513301B/zh not_active IP Right Cessation
- 2000-02-28 ES ES05018762.4T patent/ES2441208T3/es not_active Expired - Lifetime
- 2000-02-28 PL PL382172A patent/PL199660B1/pl unknown
- 2000-02-28 PT PT50187624T patent/PT1609505E/pt unknown
- 2000-02-28 PL PL350418A patent/PL197158B1/pl unknown
- 2000-02-28 SK SK5002-2008A patent/SK286775B6/sk not_active IP Right Cessation
- 2000-02-28 SK SK1225-2001A patent/SK286203B6/sk not_active IP Right Cessation
- 2000-02-28 HU HU0302780A patent/HU227602B1/hu unknown
- 2000-02-28 IL IL14485200A patent/IL144852A0/xx active IP Right Grant
- 2000-02-28 ES ES00912515T patent/ES2244413T3/es not_active Expired - Lifetime
- 2000-02-28 ID IDW00200101864A patent/ID29891A/id unknown
- 2000-02-28 DK DK00912515T patent/DK1156856T3/da active
- 2000-02-28 AU AU34253/00A patent/AU764508B2/en not_active Expired
- 2000-02-28 AT AT00912515T patent/ATE303179T1/de active
- 2000-02-28 CN CNA2004100120495A patent/CN1636562A/zh active Pending
- 2000-02-28 WO PCT/EP2000/001626 patent/WO2000051577A2/en active Application Filing
- 2000-02-28 EP EP05018762.4A patent/EP1609505B1/en not_active Expired - Lifetime
- 2000-02-28 HU HU1000576A patent/HU230044B1/hu active IP Right Revival
- 2000-02-28 KR KR1020017011098A patent/KR100839765B1/ko active IP Right Grant
- 2000-02-28 KR KR1020077029858A patent/KR100839766B1/ko active IP Right Grant
- 2000-02-28 DK DK05018762.4T patent/DK1609505T3/en active
- 2000-02-28 EP EP00912515A patent/EP1156856B1/en not_active Expired - Lifetime
- 2000-02-28 CN CNB008044929A patent/CN1195516C/zh not_active Expired - Lifetime
- 2000-02-28 BR BR0008606-1A patent/BR0008606A/pt not_active Application Discontinuation
- 2000-02-28 RU RU2001126350A patent/RU2238725C2/ru active
- 2000-02-28 CA CA002362411A patent/CA2362411C/en not_active Expired - Lifetime
- 2000-02-28 NZ NZ513716A patent/NZ513716A/en not_active IP Right Cessation
- 2000-02-28 JP JP2000602045A patent/JP4700195B2/ja not_active Expired - Lifetime
- 2000-02-28 SI SI200031078T patent/SI1609505T1/sl unknown
- 2000-02-28 DE DE60022317T patent/DE60022317T2/de not_active Expired - Lifetime
-
2001
- 2001-08-09 IL IL144852A patent/IL144852A/en not_active IP Right Cessation
- 2001-08-28 NO NO20014180A patent/NO328927B1/no not_active IP Right Cessation
-
2006
- 2006-06-13 HK HK06106764.5A patent/HK1086775A1/xx not_active IP Right Cessation
-
2008
- 2008-02-03 IL IL189190A patent/IL189190A0/en unknown
-
2009
- 2009-08-31 NO NO20092921A patent/NO334104B1/no not_active IP Right Cessation
-
2014
- 2014-02-26 CY CY20141100151T patent/CY1115241T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marusich et al. | Effects of synthetic cathinones contained in “bath salts” on motor behavior and a functional observational battery in mice | |
| DE69930552T2 (de) | Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen | |
| EP3887481A1 (en) | A method of treating refractory epilepsy syndromes using fenfluramine enantiomers | |
| CN102985085B (zh) | 治疗双相型障碍的方法 | |
| KR20070086507A (ko) | 다발성 경화증, 정서 불안정 및 가성구 정동 치료를 위한1-아미노시클로헥산 유도체 | |
| de Bruin et al. | Multiple rodent models and behavioral measures reveal unexpected responses to FTY720 and DMF in experimental autoimmune encephalomyelitis | |
| EP2288345B1 (en) | Psycho-pharmaceuticals | |
| TW202118484A (zh) | 大麻二酚於治療卓飛症候群(dravet syndrome)之用途 | |
| JP2009531431A (ja) | 認知障害および他の障害の治療方法 | |
| Mitchell et al. | Acute and chronic antidepressant drug treatments induce opposite effects in the social behaviour of rats | |
| NO334104B1 (no) | Anvendelse av fluorinerte triazoler til behandling av affektive forstyrrelser og oppmerksomhetsforstyrrelser. | |
| US20080070900A1 (en) | Method of Treating Organophosphorous Poisoning | |
| CN109475500A (zh) | 用于减低氯胺酮致精神病状副作用及成瘾疾患的方法与组合物 | |
| CA2622541C (en) | Use of fluorinated triazoles for treating neuropathic pain | |
| Cornelissen et al. | A delayed treatment model for the evaluation of scopolamine for VX nerve agent intoxication | |
| EP3544599A1 (en) | Bromide source for use in treating autism spectral disorder | |
| KR101895554B1 (ko) | 올레아놀릭산을 포함하는 신경발달장애 또는 강박장애의 예방, 개선 또는 치료용 조성물 | |
| US6156775A (en) | Use of fluorinated triazoles in treating affective and attention disorders | |
| WO2024013505A1 (en) | Ibudilast and gaboxadol for the treatment of fragile x syndrome | |
| RU2394816C1 (ru) | Нейротропное средство, обладающее антиоксидантной, противогипоксической, нейропротекторной, антиамнестической и противоукачивающей активностью и способностью улучшать когнитивные функции | |
| AU2020228149A1 (en) | Treatment of pitt-hopkins syndrome | |
| Rowley | The role of the betaine/GABA transporter in epilepsy, seizure susceptibility, and behavior | |
| Kudryavtseva et al. | New method for the study of psychotropic drug effects under simulated clinical conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |